Cargando…

Regulatory Authority Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward

INTRODUCTION: ZaZiBoNa, the work-sharing initiative in the Southern African Development Community (SADC) that has been in operation for 8 years has successfully assessed over 300 dossiers/applications, with an overall median time to recommendation of 12 months. All 16 SADC countries participate in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sithole, Tariro, Mahlangu, Gugu, Walker, Stuart, Salek, Sam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082034/
https://www.ncbi.nlm.nih.gov/pubmed/35547217
http://dx.doi.org/10.3389/fmed.2022.898743
_version_ 1784703121705926656
author Sithole, Tariro
Mahlangu, Gugu
Walker, Stuart
Salek, Sam
author_facet Sithole, Tariro
Mahlangu, Gugu
Walker, Stuart
Salek, Sam
author_sort Sithole, Tariro
collection PubMed
description INTRODUCTION: ZaZiBoNa, the work-sharing initiative in the Southern African Development Community (SADC) that has been in operation for 8 years has successfully assessed over 300 dossiers/applications, with an overall median time to recommendation of 12 months. All 16 SADC countries participate in the initiative as either active or non-active members. While the successes of ZaZiBoNa are evident, some challenges still exist. The aim of this study was to solicit the views of the participating authorities on the effectiveness and efficiency of the current operating model of the ZaZiBoNa initiative. METHODS: Data were collected in 2021 using the Process, Effectiveness and Efficiency Rating (PEER) questionnaire developed by the authors. The questionnaire was completed by the focal person in each country and approved by the head of the authority. RESULTS: ZaZiBoNa serves as a platform for work sharing, information exchange, capacity building and harmonisation of registration requirements. One of the benefits to regulators has been the improvement in the capacity to conduct assessments. Manufacturers have benefited from compiling one package (modules 2–5) for the initial submission as well as a single response package to the consolidated list of questions, which saves time and resources. Respondents were of the view that patients have benefited as the ZaZiBoNa has contributed to an improved availability and accessibility to quality-assured medicines. Some of the challenges identified were the inadequacy of resources and differences in time to the implementation of ZaZiBoNa recommendations by the individual countries. The establishment of a regional unit hosted in one of the member countries to enable centralised submission and coordination was identified as the best strategy to improve the effectiveness and efficiency of the initiative in the interim, with the long-term goal being the establishment of a regional medicines authority. CONCLUSION: The study identified the strengths of the ZaZiBoNa initiative as well as the opportunities for improvement. The recommendations made would further strengthen this initiative.
format Online
Article
Text
id pubmed-9082034
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90820342022-05-10 Regulatory Authority Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward Sithole, Tariro Mahlangu, Gugu Walker, Stuart Salek, Sam Front Med (Lausanne) Medicine INTRODUCTION: ZaZiBoNa, the work-sharing initiative in the Southern African Development Community (SADC) that has been in operation for 8 years has successfully assessed over 300 dossiers/applications, with an overall median time to recommendation of 12 months. All 16 SADC countries participate in the initiative as either active or non-active members. While the successes of ZaZiBoNa are evident, some challenges still exist. The aim of this study was to solicit the views of the participating authorities on the effectiveness and efficiency of the current operating model of the ZaZiBoNa initiative. METHODS: Data were collected in 2021 using the Process, Effectiveness and Efficiency Rating (PEER) questionnaire developed by the authors. The questionnaire was completed by the focal person in each country and approved by the head of the authority. RESULTS: ZaZiBoNa serves as a platform for work sharing, information exchange, capacity building and harmonisation of registration requirements. One of the benefits to regulators has been the improvement in the capacity to conduct assessments. Manufacturers have benefited from compiling one package (modules 2–5) for the initial submission as well as a single response package to the consolidated list of questions, which saves time and resources. Respondents were of the view that patients have benefited as the ZaZiBoNa has contributed to an improved availability and accessibility to quality-assured medicines. Some of the challenges identified were the inadequacy of resources and differences in time to the implementation of ZaZiBoNa recommendations by the individual countries. The establishment of a regional unit hosted in one of the member countries to enable centralised submission and coordination was identified as the best strategy to improve the effectiveness and efficiency of the initiative in the interim, with the long-term goal being the establishment of a regional medicines authority. CONCLUSION: The study identified the strengths of the ZaZiBoNa initiative as well as the opportunities for improvement. The recommendations made would further strengthen this initiative. Frontiers Media S.A. 2022-04-25 /pmc/articles/PMC9082034/ /pubmed/35547217 http://dx.doi.org/10.3389/fmed.2022.898743 Text en Copyright © 2022 Sithole, Mahlangu, Walker and Salek. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Sithole, Tariro
Mahlangu, Gugu
Walker, Stuart
Salek, Sam
Regulatory Authority Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward
title Regulatory Authority Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward
title_full Regulatory Authority Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward
title_fullStr Regulatory Authority Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward
title_full_unstemmed Regulatory Authority Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward
title_short Regulatory Authority Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward
title_sort regulatory authority evaluation of the effectiveness and efficiency of the zazibona collaborative medicines registration initiative: the way forward
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082034/
https://www.ncbi.nlm.nih.gov/pubmed/35547217
http://dx.doi.org/10.3389/fmed.2022.898743
work_keys_str_mv AT sitholetariro regulatoryauthorityevaluationoftheeffectivenessandefficiencyofthezazibonacollaborativemedicinesregistrationinitiativethewayforward
AT mahlangugugu regulatoryauthorityevaluationoftheeffectivenessandefficiencyofthezazibonacollaborativemedicinesregistrationinitiativethewayforward
AT walkerstuart regulatoryauthorityevaluationoftheeffectivenessandefficiencyofthezazibonacollaborativemedicinesregistrationinitiativethewayforward
AT saleksam regulatoryauthorityevaluationoftheeffectivenessandefficiencyofthezazibonacollaborativemedicinesregistrationinitiativethewayforward